Log in

OTCMKTS:ARPOAerpio Pharmaceuticals Stock Price, Forecast & News

$1.18
+0.07 (+6.31 %)
(As of 06/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.10
Now: $1.18
$1.22
50-Day Range
$0.52
MA: $0.74
$1.13
52-Week Range
$0.42
Now: $1.18
$1.53
Volume2.24 million shs
Average Volume1.32 million shs
Market Capitalization$47.89 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema. It also develops ARP-1536, a humanized monoclonal antibody that is in late stage preclinical development for the treatment of wet age-related macular degeneration; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a Phase 1a clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.
Read More
Aerpio Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.90 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ARPO
CUSIPN/A
CIKN/A
Phone513-985-1920

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$47.89 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ARPO News and Ratings via Email

Sign-up to receive the latest news and ratings for ARPO and its competitors with MarketBeat's FREE daily newsletter.

Aerpio Pharmaceuticals (OTCMKTS:ARPO) Frequently Asked Questions

How has Aerpio Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Aerpio Pharmaceuticals' stock was trading at $0.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ARPO stock has increased by 118.5% and is now trading at $1.18. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aerpio Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerpio Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Aerpio Pharmaceuticals.

How were Aerpio Pharmaceuticals' earnings last quarter?

Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) posted its quarterly earnings results on Thursday, May, 7th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.01. View Aerpio Pharmaceuticals' earnings history.

What price target have analysts set for ARPO?

1 brokerages have issued 1-year price targets for Aerpio Pharmaceuticals' stock. Their forecasts range from $1.00 to $1.00. On average, they anticipate Aerpio Pharmaceuticals' stock price to reach $1.00 in the next twelve months. This suggests that the stock has a possible downside of 15.3%. View analysts' price targets for Aerpio Pharmaceuticals.

What are Wall Street analysts saying about Aerpio Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aerpio Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Aerpio Pharmaceuticals Inc. is a biopharmaceutical company. It focuses on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye. The Company' product candidates include AKB?9778, ARP1536 and AKB-4924 which are in clinical stage. Aerpio Pharmaceuticals Inc. is based in Cincinnati, United States. " (2/13/2020)
  • 2. HC Wainwright analysts commented, "Our price target is derived from an estimated market value of the firm at $43M, which includes a discounted cash flow- based asset value for AKB-9778 in glaucoma and AKB-4924 (GB004) in inflammatory bowel disease (IBS), using a 15% discount rate and 2% terminal growth rate, and probabilities of success at 20% and 10%,." (8/9/2019)

Has Aerpio Pharmaceuticals been receiving favorable news coverage?

News headlines about ARPO stock have trended very negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Aerpio Pharmaceuticals earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutAerpio Pharmaceuticals.

Who are some of Aerpio Pharmaceuticals' key competitors?

What other stocks do shareholders of Aerpio Pharmaceuticals own?

Who are Aerpio Pharmaceuticals' key executives?

Aerpio Pharmaceuticals' management team includes the following people:
  • Dr. Joseph H. Gardner, Founder, Pres & Director (Age 62)
  • Mr. Kevin G. Peters M.D., Ph.D., Chief Scientific Officer & Sr. VP (Age 61)
  • Dr. Stephen Pakola M.D., Chief Medical Officer (Age 49)
  • Dr. Stephen J. Hoffman, CEO & Director (Age 64)
  • Mr. Michael W. Rogers, Chief Financial Officer (Age 58)

What is Aerpio Pharmaceuticals' stock symbol?

Aerpio Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ARPO."

How do I buy shares of Aerpio Pharmaceuticals?

Shares of ARPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aerpio Pharmaceuticals' stock price today?

One share of ARPO stock can currently be purchased for approximately $1.18.

How big of a company is Aerpio Pharmaceuticals?

Aerpio Pharmaceuticals has a market capitalization of $47.89 million.

What is Aerpio Pharmaceuticals' official website?

The official website for Aerpio Pharmaceuticals is www.aerpio.com.

How can I contact Aerpio Pharmaceuticals?

Aerpio Pharmaceuticals' mailing address is 9987 CARVER ROAD, CINCINNATI OH, 45242. The company can be reached via phone at 513-985-1920 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.